Intriguingly, lithium treatment in a clinical trial and models of fragile X syndrome results in amelioration of behavioral abnormalities, decreased aberrant protein synthesis rates, and substantial decreases in mTOR activity (Berry-Kravis et al., 2008; Liu et al., 2012; Liu and Smith, 2014). This evidence concerns the gene MTOR and fragile X syndrome.